Abstract
Castration-resistant prostate cancer (CRPC) is thought to be hormone driven. Inhibition of the androgen signal axis remains an important treatment strategy for CRPC. Abiraterone acetate, a selective potent inhibitor of CYP17, is able to further greatly decrease the serum testerone virtually to an undetectable level. Randomized phase III clinical trial has revealed that abiraterone acetate significantly increases PSA and tumor response rate, and prolongs time to disease progression and overall survival time. Abiraterone acetate has become a novel treatment option for CRPC patients. Abiraterone is well tolerated with a low incidence of grade 3 or 4 side effects.
| Original language | English |
|---|---|
| Pages (from-to) | 1998-2001 |
| Number of pages | 4 |
| Journal | Chinese Journal of New Drugs |
| Volume | 22 |
| Issue number | 17 |
| State | Published - Sep 15 2013 |
Keywords
- Abiraterone acetate
- Castration-resistant prostate cancer
- Pharmacokinetics
- Pharmacology